Gedatolisib
- Generic Name
- Gedatolisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H41N9O4
- CAS Number
- 1197160-78-3
- Unique Ingredient Identifier
- 96265TNH2R
- Background
Gedatolisib has been used in trials studying the basic science and treatment of Neoplasm, Ovary Cancer, Breast Cancer, Advanced Cancer, and Endometrial Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Celcuity Inc
- Target Recruit Count
- 54
- Registration Number
- NCT06190899
- Locations
- 🇪🇸
Institut Catala d'Oncologia, Barcelona, Spain
🇪🇸Hospital Clinic Barcelona, Barcelona, Spain
🇪🇸Hospital General Universitario Gregorio Maranon, Madrid, Spain
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
- Conditions
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Celcuity Inc
- Target Recruit Count
- 701
- Registration Number
- NCT05501886
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸Bond & Steele Clinic, P.A. d/b/a Bond Clinic, P.A., Winter Haven, Florida, United States
🇺🇸John D. Archbold Memorial Hospital, Thomasville, Georgia, United States
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009
- Conditions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Celcuity Inc
- Registration Number
- NCT05134922
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
- Conditions
- Interventions
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Kari Wisinski
- Target Recruit Count
- 37
- Registration Number
- NCT03911973
- Locations
- 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Registration Number
- NCT03400254
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-09
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- Kathy Miller
- Target Recruit Count
- 18
- Registration Number
- NCT03243331
- Locations
- 🇺🇸
IU Simon Cancer Center, Indianapolis, Indiana, United States
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-02-27
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 96
- Registration Number
- NCT03065062
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)
- Conditions
- Interventions
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 3
- Registration Number
- NCT02920450
- Locations
- 🇺🇸
UF Health Cancer Center, Gainesville, Florida, United States
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Celcuity Inc
- Target Recruit Count
- 141
- Registration Number
- NCT02684032
- Locations
- 🇺🇸
The Emory Clinic, Atlanta, Georgia, United States
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Karmanos Cancer Institute, Farmington Hills, Michigan, United States
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Hoffman Oncology
- Target Recruit Count
- 18
- Registration Number
- NCT02626507
- Locations
- 🇺🇸
Hoffman Oncology, Bronx, New York, United States
🇺🇸California Research Institute, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.